DCM
BCRX icon

DG Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

DG Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-203,337
Closed -$2.07M – 196
2021
Q1 		$2.07M Sell
203,337
-334,529
-62% -$3.45M 0.49% 41
2020
Q4 		$4.01M Sell
537,866
-648,860
-55% -$3.35M 1.7% 26
2020
Q3 		$4.08M Buy
1,186,726
+42,632
+4% +$183K 2.45% 18
2020
Q2 		$5.45M Buy
+1,144,094
New +$4.57M 4.47% 8

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DG Capital Management's BCRX Position: Q2 2021 in Review

DG Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 203,337 shares — an estimated $2.07M sold.

DG Capital Management first reported a position in BCRX in Q2 2020 and held it in 4 quarters. The position peaked at $5.45M in Q2 2020. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • DG Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • DG Capital Management sold 203,337 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $2.07M.
  • DG Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • DG Capital Management's BioCryst Pharmaceuticals position peaked at $5.45M in Q2 2020.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on DG Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.